Your browser doesn't support javascript.
loading
Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.
Mouraviev, V; Lee, B; Patel, V; Albala, D; Johansen, T E B; Partin, A; Ross, A; Perera, R J.
Afiliación
  • Mouraviev V; Global Robotics Institute, Florida Hospital Celebration Health, Celebration, FL, USA.
  • Lee B; Department of Integrative Metabolism, Sanford-Burnham Medical Research Institute, Orlando, FL, USA.
  • Patel V; Global Robotics Institute, Florida Hospital Celebration Health, Celebration, FL, USA.
  • Albala D; Associated Medical Professionals of New York, Syracuse, NY, USA.
  • Johansen TE; Department of Urology, Oslo University Hospital, Oslo, Norway.
  • Partin A; Brady Urology Institute, John Hopkins School of Medicine, Baltimore, MD, USA.
  • Ross A; Brady Urology Institute, John Hopkins School of Medicine, Baltimore, MD, USA.
  • Perera RJ; Department of Integrative Metabolism, Sanford-Burnham Medical Research Institute, Orlando, FL, USA.
Prostate Cancer Prostatic Dis ; 19(1): 14-20, 2016 Mar.
Article en En | MEDLINE | ID: mdl-26503110
BACKGROUND: The lack of sensitive and specific biomarkers for prostate cancer (PCa) has led to over-diagnosis and overtreatment with uncertain benefit. Therefore, biomarkers for early diagnosis that can distinguish aggressive from indolent tumors and that can detect metastatic or recurrent disease are needed. Long noncoding RNAs (lncRNAs) are non-protein-coding RNA species. lncRNAs are dysregulated in many diseases including PCa and are emerging as major players in cancer development. lncRNAs have several features that make then suitable as both biomarkers and therapeutics, and lncRNAs regulate critical cancer hallmarks in prostate epithelial cells including proliferation and survival. METHODS: The PubMed database was searched using the terms 'long noncoding RNA', 'biomarker' and 'prostate cancer'. Known lncRNAs implicated as biomarkers and potential therapeutic targets in PCa are reviewed. RESULTS: We comprehensively review several lncRNAs with potential as biomarkers for PCa. lncRNAs including PCA3, PCATs, SChLAP1, SPRY4-IT1 and TRPM2-AS are upregulated in PCa and are cancer specific; they are, therefore, attractive lead candidate biomarkers for clinical application. Several lncRNA therapeutics are currently being investigated by several companies for the treatment of various cancers including PCa. Small interfering RNAs, antisense oligonucleotides, ribozymes, deoxyribozymes and aptemers are few promising technologies for future lncRNA bases therapeutics. CONCLUSION: lncRNA expression is altered in cancer. Aberrant regulation promotes tumor formation, progression and metastasis. lncRNAs can use as tumor markers for PCa and may be attractive novel therapeutic targets for the diagnosis and treatment of PCa.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Biomarcadores de Tumor / ARN Largo no Codificante Tipo de estudio: Prognostic_studies / Screening_studies Límite: Humans / Male Idioma: En Revista: Prostate Cancer Prostatic Dis Asunto de la revista: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Biomarcadores de Tumor / ARN Largo no Codificante Tipo de estudio: Prognostic_studies / Screening_studies Límite: Humans / Male Idioma: En Revista: Prostate Cancer Prostatic Dis Asunto de la revista: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido